Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103649
Status:
COMPLETED
Last Update Posted:
2008-08-21
First Post:
2005-02-11
Brief Title:
18-Month Study of the Efficacy of Xaliproden SR57746A in Patients With Mild-to-Moderate Dementia of the Alzheimers Type
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Randomized Multicenter Double-Blind Placebo-Controlled 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimers Type
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess xaliprodens potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimers disease The patients participating in this study will take orally once daily xaliproden or placebo inactive substance pill
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SR57746 | None | None | None |